Getinge Ab Class B · OMXSTO:GETI_B

Getinge Ab Class B — Merger or Acquisition (September 2008)

11 slides from Getinge Ab Class B's merger presentation, Sep 16, 2008

1. Slide 1: Acquisition of Datascope Corp.

   GETINGE Acquisition of Datascope Corp. 16 September, 2008

2. Slide 2: Transaction Overview

   Transaction Overview BUSINESS AREA INFECTION CONTROL HEALTHCARE ƒ Getinge has signed a definitive agreement to acquire Datascope Corp. for $53.00 per share ƒ Fully diluted equity value of $865 million (SEK 5.8 billion(1)) ƒ Implied enterprise value of $618 million(2) ƒ Attractive valuation for both

3. Slide 3: Strategic Rationale

   Strategic Rationale BUSINESS AREA INFECTION CONTROL HEALTHCARE ƒ Critical mass: The acquisition of Datascope strengthens Getinge’s Cardiovascular franchise. Combined revenues will exceed $650 million ƒ The acquisition is in line with Getinge’s stated ambition of building a leading position in the at

4. Slide 4: Overview of Datascope

   Overview of INFECTION BUSINESS AREA DatascopeCONTROL HEALTHCARE ƒ Global leader in Intra-Aortic Balloon (IABP) counterpulsation therapy ƒ Operates in two divisions(1); Cardiac Assist and InterVascular ƒ 2007/08 revenue of $231 million(2) and EBITDA of $48 million, representing a 8% and 14% increase

5. Slide 5: Cardiac Assist Division Overview

   Cardiac Assist Division Overview Intra Aortic Balloon Pumps ƒ Global leader in IABP technology and a >70%(1) market share ƒ Leading market share position in both pumps and balloons ƒ Other key product lines include Catheters ƒ Endoscopic vessel harvesting devices ƒ Vascular closure products ƒ 2007/0

6. Slide 6: InterVascular Division Overview

   InterVascular Division Overview Vascular Grafts ƒ Synthetic surgical grafts and patches ƒ Recently acquired Sorin’s peripheral stent business to address $0.7 billion growing peripheral intervention market Peripheral Stents ƒ 2007/08 sales of $38.4 million ƒ 165 employees worldwide ƒ 140 in La Ciotat

7. Slide 7: Synergies

   Synergies BUSINESS AREA INFECTION CONTROL HEALTHCARE ƒ A combination of Getinge and Datascope has potential for generating significant synergies, principally from a revenue perspective ƒ Synergies will come both from product and geographic cross selling opportunities ƒ Creates a strong platform for

8. Slide 8: Key Pro Forma Financials

   Key ProAREA BUSINESS Forma Financials INFECTION CONTROL HEALTHCARE SEK, $ million Getinge Datascope(1) Pro Forma 31 December, 2007 30 June, 2008 $m SEKm Combined sales 16,445 231 1,552 17,997 EBITDA 3,222 48 321 3,543 EBITDA margin 19.6% 20.7% 20.7% 19.7% The transaction is expected to be earnings a

9. Slide 9: Financing

   Financing BUSINESS AREA INFECTION CONTROL HEALTHCARE ƒ Financed using a fully underwritten credit facility from Skandinaviska Enskilda Banken ƒ Strong cash flow from pro forma business expected to provide rapid deleveraging ƒ Part of the credit facility will be refinanced through a new share issue f

10. Slide 10: Getinge's Strategic Cornerstones

    Getinge’s Strategic BUSINESS AREA INFECTION Cornerstones CONTROL HEALTHCARE ƒ Global leadership ƒ We strive to be a global No. 1 or No. 2 in the product areas focused. Market leadership will help us attain cost leadership through scale ƒ Solution provider ƒ We strive to combine the strength of our l

11. Slide 11: Questions & Answers

    Questions & INFECTION BUSINESS AREA Answers CONTROL HEALTHCARE 11

Getinge — Merger or Acquisition (September 2008) on 6ix